Last updated 14 days ago
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
525 patients around the world
Available in Argentina, United States, Colombia, Brazil, Spain
Bristol-Myers Squibb
12Research sites
525Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Sanatorio 9 de Julio - Tucumán
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Sanatorio Allende (Nueva Córdoba)
Recruiting
Fundação Antônio Prudente - CAPEC - Centro de Apoio à Pesquisa Clínica
Recruiting
Hospital Mãe de Deus - Porto Alegre
Recruiting
Instituto Americas - COI
Recruiting
Hospital Sao Rafael
Recruiting
Hospital Pablo Tobón Uribe
Recruiting
StudySUCCESSOR-2
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Multiple myeloma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05552976
